Cases Per Condition
[By staff reporters]
***
***
***
***
Share this:
Filed under: Glossary Terms, Health Economics, LifeStyle | Tagged: corona, Covid-19, pre-existing corona conditions |
David E. Marcinko [Editor-in-Chief]
As a former Dean and appointed University Professor and Endowed Department Chair, Dr. David Edward Marcinko MBA was a NYSE broker and investment banker for a decade who was respected for his unique perspectives, balanced contrarian thinking and measured judgment to influence key decision makers in strategic education, health economics, finance, investing and public policy management.
Dr. Marcinko is originally from Loyola University MD, Temple University in Philadelphia and the Milton S. Hershey Medical Center in PA; as well as Oglethorpe University and Emory University in Georgia, the Atlanta Hospital & Medical Center; Kellogg-Keller Graduate School of Business and Management in Chicago, and the Aachen City University Hospital, Koln-Germany. He became one of the most innovative global thought leaders in medical business entrepreneurship today by leveraging and adding value with strategies to grow revenues and EBITDA while reducing non-essential expenditures and improving dated operational in-efficiencies.
Professor David Marcinko was a board certified surgical fellow, hospital medical staff President, public and population health advocate, and Chief Executive & Education Officer with more than 425 published papers; 5,150 op-ed pieces and over 135+ domestic / international presentations to his credit; including the top ten [10] biggest drug, DME and pharmaceutical companies and financial services firms in the nation. He is also a best-selling Amazon author with 30 published academic text books in four languages [National Institute of Health, Library of Congress and Library of Medicine].
Dr. David E. Marcinko is past Editor-in-Chief of the prestigious “Journal of Health Care Finance”, and a former Certified Financial Planner® who was named “Health Economist of the Year” in 2010. He is a Federal and State court approved expert witness featured in hundreds of peer reviewed medical, business, economics trade journals and publications [AMA, ADA, APMA, AAOS, Physicians Practice, Investment Advisor, Physician’s Money Digest and MD News] etc.
Later, Dr. Marcinko was a vital and recruited BOD member of several innovative companies like Physicians Nexus, First Global Financial Advisors and the Physician Services Group Inc; as well as mentor and coach for Deloitte-Touche and other start-up firms in Silicon Valley, CA.
As a state licensed life, P&C and health insurance agent; and dual SEC registered investment advisor and representative, Marcinko was Founding Dean of the fiduciary and niche focused CERTIFIED MEDICAL PLANNER® chartered professional designation education program; as well as Chief Editor of the three print format HEALTH DICTIONARY SERIES® and online Wiki Project.
Dr. David E. Marcinko’s professional memberships included: ASHE, AHIMA, ACHE, ACME, ACPE, MGMA, FMMA, FPA and HIMSS. He was a MSFT Beta tester, Google Scholar, “H” Index favorite and one of LinkedIn’s “Top Cited Voices”.
Marcinko is “ex-officio” and R&D Scholar-on-Sabbatical for iMBA, Inc. who was recently appointed to the MedBlob® [military encrypted medical data warehouse and health information exchange] Advisory Board.
Ann Miller RN MHA [Managing Editor]
ME-P SYNDICATIONS:
WSJ.com,
CNN.com,
Forbes.com,
WashingtonPost.com,
BusinessWeek.com,
USNews.com, Reuters.com,
TimeWarnerCable.com,
e-How.com,
News Alloy.com,
and Congress.org
PodiatryPrep.org
BOARD CERTIFICATION EXAM STUDY GUIDES
Lower Extremity Trauma
[Click on Image to Enlarge]ME-P Free Advertising Consultation
The “Medical Executive-Post” is about connecting doctors, health care executives and modern consulting advisors. It’s about free-enterprise, business, practice, policy, personal financial planning and wealth building capitalism. We have an attitude that’s independent, outspoken, intelligent and so Next-Gen; often edgy, usually controversial. And, our consultants “got fly”, just like U. Read it! Write it! Post it! “Medical Executive-Post”. Call or email us for your FREE advertising and sales consultation TODAY [770.448.0769]
Medical & Surgical e-Consent Forms
ePodiatryConsentForms.comME-P Publishing
Start-Up Advice for Businesses, DRs and Entrepreneurs
“Providing Management, Financial and Business Solutions for Modernity”
Capitalism and Free Enterprise Advocacy
Whether you’re a mature CXO, physician or start-up entrepreneur in need of management, financial, HR or business planning information on free markets and competition, the "Medical Executive-Post” is the online place to meet for Capitalism 2.0 collaboration.
Support our online development, and advance our onground research initiatives in free market economics, as we seek to showcase the brightest Next-Gen minds.
THE ME-P DISCLAIMER: Posts, comments and opinions do not necessarily represent iMBA, Inc., but become our property after submission. Copyright © 2006 to-date. iMBA, Inc allows colleges, universities, medical and financial professionals and related clinics, hospitals and non-profit healthcare organizations to distribute our proprietary essays, photos, videos, audios and other documents; etc. However, please review copyright and usage information for each individual asset before submission to us, and/or placement on your publication or web site. Attestation references, citations and/or back-links are required. All other assets are property of the individual copyright holder.
OIG Fraud Warnings
INTERESTING
Some physicians, like Ram Yogendra, MD, MPH strongly believe that COVID-D is not really a “respiratory-lung” disease, but rather a disease
of hemoglobin pathology. He presents convincing evidence of the hemoglobin failure, because like malaria itself, the virus attacks the hemoglobin molecule directly.
Other physicians, like Dr. Jaime Lucio Pascual Ballesteros, point to direct evidence of hemoglobinopathy:
So, has led this some to come to the conclusion that treating this condition like a pulmonary infection is incorrect. And, this has been
borne out by the failure of ventilation therapy?
Any thoughts?
Conrad
LikeLiked by 1 person
The WHO
A document posted on the World Health Organization’s website yesterday delivered some disappointing news: Remdesivir, a potential COVID-19 treatment developed by biopharma company Gilead Sciences, did not improve patient outcomes in a randomized clinical trial.
According to the summary, 13.9% of the patients who received the drug died after one month, versus 12.8% in a control group, the FT and health news site Stat report.
The twist: The summary was quickly removed from the website. A WHO spokesperson said it was posted by mistake.
The study, a first-of-its-kind clinical trial in China, was stopped early because it didn’t have enough patients, so Gilead argued its results are inconclusive. Although Gilead did say “trends in the data suggest a potential benefit” for the drug.
So … what does it all mean?
Not much—no definitive thumbs up or down for remdesivir yet.
Several other ongoing studies will hopefully offer more conclusion.
Nigel
LikeLike
Money Quote:
Dr. Zhang said, “I would suggest three consecutive negative RT-PCR results to safely discharge, due to high false-negative rate. . .”
Dr. Jack Lipton, (Department Chair at MSU). . . commented. . ., “The study demonstrates that repeated testing is absolutely necessary. In our clinical trial of university personnel at MSU, we have a young healthy subject with mild symptoms who has tested positive five times over four weeks. People need to realize that a 14-day isolation is appropriate for seeing whether one will develop symptoms after a known exposure to an infected person. Fourteen days is not a sufficient amount of time to be infected, recover and then be virus free.”
Anonymous
LikeLiked by 1 person